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Lymphoma is the most common hematological malignancy in developed countries. Outcome is strongly determined by
molecular subtype, reflecting a need for new and improved treatment options. Dogs spontaneously develop lymphoma,
and the predisposition of certain breeds indicates genetic risk factors. Using the dog breed structure, we selected three lym-
phoma predisposed breeds developing primarily T-cell (boxer), primarily B-cell (cocker spaniel), and with equal distribution
of B- and T-cell lymphoma (golden retriever), respectively. We investigated the somatic mutations in B- and T-cell lympho-
mas from these breeds by exome sequencing of tumor and normal pairs. Strong similarities were evident between B-cell
lymphomas from golden retrievers and cocker spaniels, with recurrent mutations in TRAF3-MAP3K14 (28% of all cases),
FBXW7 (25%), and POT1 (17%). The FBXW7 mutations recurrently occur in a specific codon; the corresponding codon is re-
currently mutated in human cancer. In contrast, T-cell lymphomas from the predisposed breeds, boxers and golden retriev-
ers, show little overlap in their mutation pattern, sharing only one of their 15 most recurrently mutated genes. Boxers, which
develop aggressive T-cell lymphomas, are typically mutated in the PTEN-mTOR pathway. T-cell lymphomas in golden re-
trievers are often less aggressive, and their tumors typically showed mutations in genes involved in cellular metabolism. We
identify genes with known involvement in human lymphoma and leukemia, genes implicated in other human cancers, as well
as novel genes that could allow new therapeutic options.
[Supplemental material is available for this article.]
Diffuse large B-cell lymphoma (DLBCL) is a genetically heteroge-
neous, aggressive form of non-Hodgkin lymphoma (NHL) and
the most prevalent form of B-cell NHL in people. Approximately
30,000 DLBCL cases are diagnosed each year in the United
States, of which only half are curable (Abramson and Shipp
2005). Molecular subclassifications of DLBCL are highly predictive
of treatment outcome (Alizadeh et al. 2000). NHL can also arise
from T cells, making up 10%–15% of all NHL cases. T-cell lympho-
mas are highly heterogeneous and several subtypes exist (Evens
and Gartenhaus 2003; Iqbal et al. 2010).
Dogs have previously been proven useful in determining pre-
disposing genetic markers for human diseases due to the breed
structure caused by artificial breeding for phenotypic factors
(Dodman et al. 2010; Wilbe et al. 2010; Shearin et al. 2012;
Karlsson et al. 2013; Tang et al. 2014). A recent lymphoma study
in dogs identified a gene (TRAF3) as being commonly mutated
in both dog and human B-cell lymphomas (Bushell et al. 2015).
However, this study did not separate canine tumors based on
breed, preventing the discoveryof somaticmutations reflecting ge-
netic background. Since dog breeds represent genetic isolates,
comparing dog breeds with differential predispositions to cancer
can indicate the role of the genetic background and allow for better
detection of mutations influenced by that genetic background. In
dogs, malignant lymphoma is the most common tumor treated
with chemotherapy, affecting dogs of all ages and breeds (Valli
et al. 2013); however, the high rate of lymphoma in certain breeds
and preferential cells of origin among different breeds indicates ge-
netic risk factors (Modiano et al. 2005).Present addresses:
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Approximately 70% of all canine lymphomas arise from
B cells (Modiano et al. 2005; Ponce et al. 2010). Themost common
form of canine B-cell lymphoma is the clinical and histological
equivalent of human DLBCL (Vail and MacEwen 2000; Modiano
et al. 2005; Valli et al. 2011; Ito et al. 2014). As in humans, the
CHOP-based chemotherapy protocols are the most effective treat-
ment for canine B-cell lymphomas. T-cell lymphomas are less
common in dogs, and the most aggressive types have a higher
risk of relapse and early death (Ruslander et al. 1997; Dobson
et al. 2001).Many T-cell lymphomas also have a low long-term sur-
vival frequency in humans.
Exome sequencing efforts in human lymphomas have shown
that certain mutations are specific for lymphoma subtypes or
shared between only a few subtypes (Zhang et al. 2014). For exam-
ple, DLBCL typically have mutations affecting B-cell receptor sig-
naling or subunits, e.g., CD79A/B, and in histone modifiers like
EZH2 and MLL2, PRDM1, TP53, CARD11, and MYD88 (Lenz
et al. 2008; Davis et al. 2010; Mandelbaum et al. 2010; Morin
et al. 2010; Ngo et al. 2011; Lohr et al. 2012).MYD88 is also recur-
rentlymutated in other B-cell lymphomas like primary central ner-
vous system lymphoma (PCNSL) (Gonzalez-Aguilar et al. 2012),
and MLL2 and TP53 mutations have been reported for mantle
cell lymphoma (MCL) (Zhang et al. 2014). The two main human
DLBCL subtypes—activated B cell (ABC) and germinal center
B cell (GCB)—which can be distinguished based on differential
gene expression and prognosis (Alizadeh et al. 2000), also have
unique recurrent mutations. ABC DLBCLs are characterized by
mutations in B-cell differentiation genes and often show constitu-
tive activation of NF-κB signaling, whereas BCL2 and MYC trans-
locations are characteristic of GCB DLBCLs (summarized in
Pasqualucci et al. 2011b). Canine B-cell lymphomas can also be
separated into germinal and post-germinal center types using
gene expression data, sharing pathways with their human coun-
terparts (Richards et al. 2013), although more studies are needed
to fully elucidate this. T-cell lymphomas are much less studied
compared with B-cell lymphomas, particularly DLBCL.
The treatment outcome of canine lymphoma is predictive of
the human response to the same treatment (Honigberg et al. 2010;
Marconato et al. 2013; London et al. 2014), and canine clinical tri-
als, although highly regulated, are easier to complete compared
with human trials. Hence, a better under-
standing of canine lymphoma offers
great potential to accelerate develop-
ment of new treatments for human pa-
tients. Here, we have compared the
somaticmutations of B- and T-cell canine
lymphoma in three dog breeds with dif-
ferent lymphoma immunophenotype
predispositions. The identified breed-
specific patterns are a good opportunity
to study interventions targeting the sig-
nificant mutations.
Results
General mutation load and significantly
mutated genes
To allow detection of typical B- and T-cell
lymphoma tumor mutations in different
genetic backgrounds, samples were col-
lected from three dog breeds predisposed
to different lymphoma subtypes (Modiano et al. 2005). This is the
largest canine lymphoma exome sequencing effort to date. The av-
erage lymphoma incidence has been estimated as 20–100 cases per
100,000 dogs (Ito et al. 2014). Golden retrievers in the United
States are predisposed to both B- and T-cell lymphoma, with
13%developing lymphoma, and >60%developing cancer general-
ly (Glickman et al. 2000). B- and T-cell lymphoma is equally com-
mon in this breed, indicating that they are relatively more
predisposed to T-cell lymphoma, which normally makes up one-
third of the lymphoma cases (Modiano et al. 2005). Boxers also
show lymphoma predisposition (Modiano et al. 2005), and
∼90% of their lymphomas originate from T cells (Modiano et al.
2005; Pastor et al. 2009). For a breed typically developing B-cell
lymphomas (relative frequency about 9:1 for B:T-cell), cocker
spaniels were chosen (Modiano et al. 2005). The differential predis-
position to lymphoma arising from different cell types reflects the
homogeneous genetic backgrounds of dog breeds, different among
breeds but relatively homogeneous within each breed. All three
breeds chosen were created independently ∼200 yr ago, and are
not related beyond the species level (Vaysse et al. 2011). The num-
ber of sequenced samples is shown in Figure 1; 64 B-cell lympho-
mas (54 from golden retriever [Gr B-cell] and 10 from cocker
spaniel [Cs B-cell]) and 41 T-cell lymphomas (25 from golden re-
triever [Gr T-cell] and 16 from boxer [Bx T-cell]). The difference
in sample group sizes reflects both the popularity of and the
lymphoma frequency in each breed. The analysis pipeline is out-
lined in Figure 1.Matched tumor andnormal sampleswere collect-
ed, and their exomes were captured via a Roche custom designed
canine exome (50 Mb) followed by sequencing by Illumina (aver-
age depth normal 72×, tumor 93×). MuTect (Cibulskis et al.
2013) and IndeLocator (http://www.broadinstitute.org/cancer/
cga/indelocator) were used to call variants and identify somatic
mutations, which were then annotated with SnpEff (Cingolani
et al. 2012). On average, 476 somatic mutations, of which 18
were nonsilent protein-coding mutations, were identified in each
sample. T-cell lymphomas had a higher average load of nonsilent
protein-coding mutations compared to B-cell lymphomas (23 ver-
sus 15 per sample, Pt-test = 2.3 × 10
−3) (Fig. 1). The overall pattern of
somatic mutations was similar across the breed and lymphoma
immunophenotype groups (Supplemental Fig. S1), but golden
Figure 1. Analysis pipeline and mutation number overview. (A) Sample numbers and average muta-
tions per breed and immunophenotype are indicated. (B) Exome libraries were sequenced and variants
were called with MuTect, a caller adapted for cancer data, and IndeLocator. Somatic variants were anno-
tated using SnpEff. MuSiC was used for identification of significantly mutated genes.
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retrievers have on average 33% fewer total mutations compared to
the other two breeds (pt-test = 2.8 × 10
−6) (Fig. 1). The number of
somatic mutations did not increase with sequencing depth
(Supplemental Fig. S2), indicating that the sequencing was deep
enough to comprehensively identify mutations and use these for
comparison between breeds and tumor types.
The nonsilent coding mutations, around 18 per sample (Fig.
1; Supplemental Table S1), were used to identify significantly mu-
tated genes using the Genome MuSiC tool (Dees et al. 2012). The
number of significantly mutated genes largely reflects the number
of input samples. The vastmajority (93%, 87 of 94) of significantly
somatically mutated genes were significantly mutated in only one
lymphoma immunophenotype group (Fig. 2). The topmost signif-
icantlymutated genes in B-cell lymphomas are POT1, FBXW7, and
TRAF3 (Table 1; Supplemental Table S2). Other B-cell lymphoma
defining genes include the FAM90A1 uncharacterized protein,
the tumor suppressor TP53, the RNA helicaseDDX3X, proteasome
subunit PSMA1, proline-rich nuclear receptor coactivator 1
(PNRC1), SET-domain containing 2 (SETD2), andmitogen-activat-
ed protein kinase kinase kinase 14 (MAP3K14). The large majority
of those have high protein identitywith their human counterparts
(Supplemental Table S3A). Notably, TRAF3 and MAP3K14 (NIK)
act in the same complex in the alternative NF-κB pathway. Both
have been reported as mutated in human classical Hodgkin lym-
phoma (Otto et al. 2012) as well as mantle cell lymphoma, where
MAP3K14 was recently reported as a new therapeutic target (Rahal
et al. 2014). NF-κB pathway deregulation is also a feature of many
DLBCL tumors (Compagno et al. 2009).DDX3X has been reported
to be mutated in Burkitt’s lymphoma (Richter et al. 2012). SETD2
is a histone methyltransferase. Several histone methyltransferases
(primarily MLL2, EZH2) and acetyltransferases (typically CREBBP,
EP300) have been implicated in human lymphoma (Morin et al.
2011; Pasqualucci et al. 2011a,b). As described for human
DLBCL (Pasqualucci et al. 2011b), mutations in these genes are
largely mutually exclusive among the studied B-cell lymphomas
(Supplemental Fig. S3). In the T-cell lymphoma cohort, the most
significantly mutated genes (Table 2) are SATB homeobox 1
(SATB1), followed by TBC1D26 (uncharacterized protein), protea-
some subunit PSMA1, cytochrome c oxidase subunit VIIIA
(COX8A), and tumor suppressor PTEN. About half of the most sig-
nificantlymutated genes in this study have been implicated in hu-
man lymphoma, but there are also several hits that have not
previously been reported in human cancer studies, such as genes
from theNLRP family, with a role in innate immunity. In addition,
a smaller fraction of the significantly mutated genes, such as
PSMA1 and KPNA2, have not been reported in human lymphoma
but have been reported in other human cancers.
B-cell tumor mutations are more uniform than
T-cell tumor mutations
Only seven genes (7%)were significantly (as determined byMuSiC
analysis) mutated in both lymphoma immunophenotype groups,
such as the proteasome subunit gene PSMA1, and the genes encod-
ing the two uncharacterized proteins FAM90A1 and TBC1D26.
With few exceptions, most genes are significantly mutated in
either B- or T-cell lymphoma andnot in both (Fig. 2; Supplemental
Table S2).
B-cell lymphoma-defining genes show striking similarities
between the two predisposed breeds. Of all significantly mutated
genes in cocker spaniel B-cell lymphomas, 62.5% (5 of 8) are also
among the 15 most significantly mutated golden retriever B-cell
lymphoma genes (Fig. 2). Of the four top significant genes, two
are shared. In contrast, among T-cell lymphomas, the significantly
mutated genes aremost often confined to only one breed (Table 2).
The effects of thesemutationswere estimated using Ingenuity
Pathway Analysis (IPA; http://www.ingenuity.com) on the signifi-
cantlymutated genes for each breed and tumor type. As themajor-
ity of significantly mutated canine genes have high protein
identity with their human orthologs, pathways are expected to
be conserved between canine and human. As expected from their
differential sharing of typical mutations, the canonical pathways
altered are highly overlapping between cocker spaniel and golden
retriever B-cell lymphomas, and they are very different between
boxer and golden retriever T-cell lymphomas. Seventy-five percent
(34 of 46) of all canonical pathways altered by the genes that
are significantlymutated inCs B-cell lymphomas are also implicat-
ed for the Gr B-cell lymphoma tumors (Table 3; Supplemental
Table S4). In contrast, only 15% of the Bx T-cell lymphoma canon-
ical pathways are also implicated in Gr T-cell lymphoma tumors
(Table 4; Supplemental Table S5). A similar pattern is seen when































Figure 2. Overlap of significantlymutated genes. (A) The two B-cell lymphoma predisposed breeds share some of their most significantlymutated genes.
(B) The two T-cell lymphoma predisposed breeds do not share any top significantlymutated genes. (C) There is some overlap in significantly mutated genes




mutated genes using DAVID (Huang da et al. 2009a,b) are com-
pared.
Somatic copy number alterations (SCNAs) estimated from
the exome sequencing data confirm the differences between
B- and T-cell lymphomas. The most significant alterations are de-
letions in part of the T-cell receptor (TCR), which are typically
seen in lymphomas originating from T cells (Pt-test = 1.7 × 10
−7),
and deletions in two immunoglobulin genes, more commonly
seen in lymphomas originating from B cells (Table 5; Supplemen-
tal Table S6). These deletions are likely not a cancer-driven alter-
ation, but rather TCR and immunoglobulin gene diversity
reflecting the tumor cell of origin. In addition, the detected
SCNAs (Supplemental Fig. S4) showoverlapwith a fewof the recur-
rently mutated genes, such as KLRK1, a member of the killer cell
lectin-like receptor subfamily K, and PKD1, which encodes a poly-
cystin protein involved in cell–cell/matrix interactions and with a
role in cell migration and invasion in human osteosarcoma
(Onishi et al. 2012). The SCNAs are seen in both B- and T-cell
Table 1. Top significantly mutated genes in B-cell lymphoma and their mutation frequency
Gene ID P-value CT FDR CT
Cs B-cell (n = 10)
(%)
Gr B-cell (n = 54)
(%)
All B-cell (n = 64)
(%)
All T-cell (n = 41)
(%)
Cocker spaniel
FAM90A1 3.47 × 10−9 8.51 × 10−5 30.0 13.0 15.6 7.3
DDX3X 1.72 × 10−8 2.10 × 10−4 30.0 7.4 10.9 0
TRAF3 6.44 × 10−8 5.26 × 10−4 30.0 18.5 20.3 0
MITF 1.70 × 10−7 1.04 × 10−3 20.0 0 3.1 0
PSMA1 4.11 × 10−7 2.02 × 10−3 20.0 5.6 7.8 9.8
MYC 1.46 × 10−6 5.98 × 10−3 20.0 0 3.1 0
GRIFIN 6.07 × 10−6 2.13 × 10−2 20.0 0 3.1 4.9
POT1 8.15 × 10−6 2.22 × 10−2 20.0 16.7 17.2 0
Golden retriever
FBXW7 0.00 × 10+0 0.00 × 10+0 10.0 27.8 25.0 4.9
POT1 1.10 × 10+22 1.34 × 10−18 20.0 16.7 17.2 0
TRAF3 1.56 × 10−19 1.28 × 10−15 30.0 18.5 20.3 0
FAM90A1 2.36 × 10−18 1.45 × 10−14 30.0 13.0 15.6 7.3
ENSCAFG00000031638 5.30 × 10−18 2.60 × 10−14 10.0 13.0 12.5 9.8
TP53 2.25 × 10−17 9.18 × 10−14 20.0 14.8 15.6 4.9
PNRC1 1.07 × 10−12 3.76 × 10−9 0 9.3 7.8 4.9
FKBP3 1.26 × 10−9 3.32 × 10−6 0 5.6 4.7 0.0
TBC1D26 1.13 × 10−9 3.32 × 10−6 10.0 7.4 6.3 14.6
RPL23A 1.35 × 10−9 3.32 × 10−6 10.0 3.7 6.3 4.9
FAM90A1 6.43 × 10−9 1.43 × 10−5 30.0 13.0 15.6 7.3
SOCS2 7.75 × 10−9 1.58 × 10−5 0 5.6 4.7 2.4
PSMA1 1.21 × 10−08 2.28 × 10−05 20.0 5.6 7.8 9.8
DDX3X 1.99 × 10−8 3.48 × 10−5 30.0 7.4 10.9 0
SETD2 3.33 × 10−8 5.44 × 10−5 20.0 11.1 12.5 2.4
Table 2. Top significantly mutated genes in T-cell lymphoma and their mutation frequency
Gene ID P-value CT FDR CT
Bx T-cell (n = 16)
(%)
Gr T-cell (n = 25)
(%)
All T-cell (n = 41)
(%)
All B-cell (n = 64)
(%)
Boxer
PTEN 2.52 × 10−11 6.19 × 10−7 25.0 0 9.8 0
SATB1 3.61 × 10−10 4.42 × 10−6 25.0 12.0 17.1 0
MAP2K1 2.28 × 10−6 1.86 × 10−2 12.5 0 4.9 0
EEF1A1 6.40 × 10−6 3.26 × 10−2 0 12.0 1.6 7.3
NLRP14 6.64 × 10−6 3.26 × 10−2 12.5 0 4.9 1.6
KCND2 1.22 × 10−5 4.99 × 10−2 12.5 0 4.9 1.6
Golden retriever
PSMA1 4.86 × 10−13 1.19 × 10−8 6.3 16.0 9.8 7.8
COX8A 1.51 × 10−11 1.85 × 10−7 0 12.0 7.3 0
LTA4H 1.95 × 10−9 1.19 × 10−5 0 16.0 9.8 1.6
TBC1D26 1.57 × 10−9 1.19 × 10−5 6.3 20.0 14.6 6.3
ZNF706 1.77 × 10−8 8.69 × 10−5 0 8.0 4.9 0
ATP5H 7.49 × 10−8 3.06 × 10−4 0 8.0 4.9 3.1
ENSCAFG00000031638 1.45 × 10−7 5.09 × 10−4 6.3 12.0 9.8 12.5
PTPN6 3.23 × 10−7 9.91 × 10−4 0 12.0 7.3 0
NLRP5 3.68 × 10−7 1.00 × 10−3 0 12.0 7.3 1.6
GLUD2 6.04 × 10−7 1.48 × 10−3 0 12.0 7.3 3.1
RPL11 6.92 × 10−7 1.54 × 10−3 0 8.0 4.9 0
SATB1 3.44 × 10−6 7.04 × 10−3 25.0 12.0 17.1 0
RPL23A 4.08 × 10−6 7.70 × 10−3 0 8.0 4.9 6.3
KRTAP10-6 5.13 × 10−6 8.98 × 10−3 0 12.0 7.3 0
MAGEC2 6.38 × 10−6 1.04 × 10−2 0 8.0 4.9 0
Lymphoma tumor mutations in dog genetic isolates
Genome Research 1637
www.genome.org
lymphomas, although these two genes are only significantly mu-
tated in B-cell lymphomas.
B-cell lymphoma defining pathways point to the importance
of telomerase and autoimmunity
The pathways affected by typical B-cell lymphoma tumor muta-
tions highlight the importance of telomerase and proliferation
signaling for successful tumor development, as well as path-
ways involved in autoimmunity. The top network estimated by
IPA for the combined B-cell lymphoma data set is “Cancer,
Hematological Disease, Immunological Disease” (Supplemental
Table S7). The canonical pathways identified for the two B-cell
lymphoma data sets, when analyzed separately as well as together,
include pathways for specific cancers, telomerase signaling path-
ways, and pathways associated with proliferation/apoptosis and
autoimmune disorders, such as TWEAK signaling, APRIL-mediated
signaling, and the STAT3 pathway (Table 3; Supplemental Table
S4). Cell death and immunity (CD40L andTNF receptor and ligand
signaling) were also reported when the top significantly mutated
genes were functionally annotated using DAVID (Huang da et al.
2009a,b) (Supplemental Table S8).
POT1, themost significantly somatically mutated gene in the
Gr and Cs B-cell lymphomas combined, encodes a protein impor-
tant for telomere maintenance, and mutations in this gene predis-
pose to several types of cancer in human (Robles-Espinoza et al.
2014; Shi et al. 2014). The gene is also recurrently mutated, lost,
or differentially regulated in human cancers, including lymphoma
(Bellon et al. 2006; Vega et al. 2008).
The second most significantly mutated gene among all B-cell
lymphomascombined is themostcommonlymutatedgeneamong
Gr B-cell lymphomas alone. This gene encodes the E3 ubiquitin
ligase FBXW7, which targets cyclin E for degradation (Koepp
et al. 2001) and controls the stability of MYC (Yada et al. 2004).
FBXW7 has been shown to be recurrently mutated at two
amino acid positions in human cancers (Lawrence et al. 2014). As
shown in Figure 3, 41%of all FBXW7mutations in our lymphomas
occur at the corresponding codon as one of those positions (canine
R470, equivalent to human R465) (see Supplemental Table S3B).
Notably, FBXW7 is much more recurrently mutated in Gr B-cell
than Cs B-cell lymphomas, and it is also mutated in a few Gr T-
cell lymphomas but none of the studied Bx T-cell lymphomas.
Table 3. Canonical pathways (P < 0.01) suggested by IPA for signifi-
cantly mutated genes from B-cell lymphomas from cocker spaniel,
golden retriever, and both breeds combined
P-value Genes
Cocker spaniel
Small cell lung cancer signaling 2.57 × 10−4 MYC,TRAF3
Telomerase signaling 5.01 × 10−4 MYC,POT1
Role of macrophages, fibroblasts and
endothelial cells in rheumatoid
arthritis
4.37 × 10−3 MYC,TRAF3
Telomere extension by telomerase 5.25 × 10−3 POT1
Polyamine regulation in colon
cancer
7.59 × 10−3 MYC
Estrogen-mediated S-phase entry 8.32 × 10−3 MYC
Golden retriever
NGF signaling 1.91 × 10−3 TP53,MAP3K14,
NTRK1
TWEAK signaling 2.75 × 10−3 MAP3K14,TRAF3
APRIL-mediated signaling 3.39 × 10−3 MAP3K14,TRAF3
Role of PKR in interferon induction
and antiviral response
3.80 × 10−3 TP53,TRAF3
B-cell activating factor signaling 3.80 × 10−3 MAP3K14,TRAF3
Thyroid cancer signaling 3.80 × 10−3 TP53,NTRK1
Glutamate biosynthesis II 4.57 × 10−3 GLUD2
Glutamate degradation X 4.57 × 10−3 GLUD2
Role of Oct4 in mammalian
embryonic stem cell pluripotency
5.01 × 10−3 TP53,PHC3
Lymphotoxin β receptor signaling 6.76 × 10−3 MAP3K14,TRAF3
NF-κB signaling 7.24 × 10−3 MAP3K14,
TRAF3, NTRK1
Induction of apoptosis by HIV1 8.32 × 10−3 TP53,MAP3K14
CD40 signaling 9.77 × 10−3 MAP3K14,TRAF3
Cocker spaniel + golden retriever
Thyroid cancer signaling 1.17 × 10−4 TP53,MYC,
NTRK1
Small cell lung cancer signaling 6.46 × 10−4 TP53,MYC,
TRAF3
STAT3 pathway 7.08 × 10−4 MYC,NTRK1,
SOCS2
Telomerase signaling 1.70 × 10−3 TP53,MYC,POT1
NGF signaling 2.14 × 10−3 TP53,MAP3K14,
NTRK1
TWEAK signaling 2.95 × 10−3 MAP3K14,TRAF3
APRIL-mediated signaling 3.72 × 10−3 MAP3K14,TRAF3
Role of PKR in interferon induction
and antiviral response
4.07 × 10−3 TP53,TRAF3
B-cell activating factor signaling 4.07 × 10−3 MAP3K14,TRAF3
Melanoma signaling 4.57 × 10−3 TP53,MITF
Table 4. Top canonical pathways suggested by IPA for significantly
mutated genes from T-cell lymphomas from boxer and golden
retriever
Ingenuity canonical pathways P-value Ratio Genes
Boxer
Melanoma signaling 6.31 × 10−5 0.0476 MAP2K1,
PTEN
Endometrial cancer signaling 9.77 × 10−5 0.0385 MAP2K1,
PTEN
ERBB2-ERBB3 signaling 1.17 × 10−4 0.0351 MAP2K1,
PTEN
IL-17A signaling in airway cells 1.48 × 10−4 0.0312 MAP2K1,
PTEN
Prostate cancer signaling 2.45 × 10−4 0.0244 MAP2K1,
PTEN
FAK signaling 2.75 × 10−4 0.023 MAP2K1,
PTEN
Neuregulin signaling 2.82 × 10−4 0.0227 MAP2K1,
PTEN
Glioma signaling 3.31 × 10−4 0.0211 MAP2K1,
PTEN
PTEN signaling 5.01 × 10−4 0.0169 MAP2K1,
PTEN
PI3K/AKT signaling 5.50 × 10−4 0.0163 MAP2K1,
PTEN
PI3K signaling in B
lymphocytes
5.89 × 10−4 0.0156 MAP2K1,
PTEN
Ovarian cancer signaling 6.17 × 10−4 0.0153 MAP2K1,
PTEN




7.76 × 10−4 0.0137 MAP2K1,
PTEN
RAR activation 1.12 × 10−3 0.0114 MAP2K1,
PTEN
Golden retriever
Glutamate biosynthesis II 1.70 × 10−3 0.5 GLUD2
Glutamate degradation X 1.70 × 10−3 0.5 GLUD2
Oxidative phosphorylation 3.80 × 10−3 0.0183 ATP5H,
COX8A
Arginine biosynthesis IV 5.01 × 10−3 0.167 GLUD2





The TNF-receptor associated factor TRAF3 is part of the CD40
signaling cascade regulating proliferation, immunoglobulin class
switching, and apoptosis (Rousset et al. 1991; Tsubata et al.
1993; Kornbluth et al. 2012). TRAF3 also acts in a complex with
TRAF2, BIRC2 (cIAP1), and BIRC3 (cIAP2) to target MAP3K14
(NIK) for degradation, thereby regulating the alternative NF-κB
pathway regulating proliferation, B-cell activation, and other pro-
cesses (for review, see Sun 2011). TRAF3 alone is mutated in 30%,
and either or both TRAF3 andMAP3K14 aremutated in 50% of the
cocker spaniel B-cell lymphomas and 30% of all golden retriever B-
cell lymphomas—those two genes are also commonly seenmutat-
ed in human classical Hodgkin’s lymphoma (Table 1; Otto et al.
2012). A recent study, inspired by TRAF3 mutations in canine B-
cell lymphoma RNA-seq showed that TRAF3 loss resulting in de-
creased gene expression is a feature of some human DLBCLs
(Bushell et al. 2015). The TRAF3 gene is also significantly mutated
in multiple myeloma (Lawrence et al. 2014). BIRC3 is mutated in
mantle cell lymphoma and GCB DLBCL but not in Burkitt’s lym-
phoma or ABC DLBCL (Zhang et al. 2014).
FAM90A1, the fourthmost significantlymutated gene among
B-cell lymphomas (16%) belongs to a gene family with 25 mem-
bers in the humangenome, several resulting fromaprimate-specif-
ic gene duplication (Bosch et al. 2007). Dogs have four paralogs, of
which only one is recurrently mutated in B-cell lymphoma. The
same paralog is mutated in 7% of the T-cell lymphomas. The clus-
tering of the mutations in this gene suggests that they are func-
tionally relevant. The exact function of this gene is unknown.
Mutation patterns in T-cell lymphoma predisposed breeds
overlap very little
In contrast to B-cell lymphomas, the T-cell lymphoma defining
genes are largely not shared between the two predisposed breeds
(golden retrievers and boxers). Of the 15most commonlymutated
genes in each of the two predisposed breeds, only one is shared
(SATB1). Of the six significantly mutated genes identified in Bx
T-cell lymphomaswithMuSiC analysis, only one, SATB1, is report-
ed mutated among the Gr T-cell lymphoma tumors (Table 2).
Since the significantly mutated genes in the two T-cell lym-
phoma breeds were very different, they were analyzed separately
with IPA. The respective networks are not shared. Top networks
are “Cellular Development, Cellular Growth and Proliferation,
Cellular Movement” for Bx T-cell and “Connective Tissue
Development and Function, Tissue Morphology, Cell-To-Cell
Signaling and Interaction” for Gr T-cell lymphoma (Supplemental
Table S9). Similarly, functional annotation charts generated using
DAVID implicates cell adhesion and cell migration for the Boxer
significantly mutated genes, whereas the gene ontology terms as-
sociated with the top significantly mutated genes from Gr T-cell
lymphomas mostly revolve around ribosomes and mitochondria.
The canonical pathway suggested to be affected for Bx T-cell lym-
phomas reflect the recurrent mutations in PTEN and MAP2K1;
these two genes are mutated in 38% of all Bx T-cell lymphomas
and not in a single Gr T-cell lymphoma or any of the B-cell lym-
phomas in this study (Table 2).
Bx T-cell lymphomas were typically mutated in SATB1 and
PTEN. SATB1 is a matrix protein recruiting chromatin remodeling
factors, thereby regulating chromatin state and gene expression.
This gene was mutated in 25% of all Bx and 12% of the Gr T-cell
lymphomas. The well-known tumor suppressor gene PTEN is mu-
tated in 25% of all Bx and none of the Gr T-cell lymphomas.
Several human cancers show deregulation of the PI3K pathway
(Samuels et al. 2004). The PI3KCD, PIK3RI, and MTOR genes
have been reported to be mutated in occasional DLBCL cases
(Zhang et al. 2013). PTEN antagonizes the PI3K-AKT-mTOR path-
way (Maehama and Dixon 1998; for review, see Song et al. 2012;
Worby and Dixon 2014), and at least one of those four genes are
mutated in almost half (44%) of all Bx T-cell lymphomas but
only in 6% of all Gr T-cell lymphomas (Table 2), suggesting that
this pathway is highly important for Bx T-cell lymphoma develop-
ment.Hypothesizing that itmay be something in the genetic back-
ground of boxers that increases their likelihood of getting
mutations in the PTEN-mTOR pathway, other important genes
connected to this pathway were evaluated for germline mutations
in exome-sequenced blood DNA from boxers and non-boxers,
identifying a nonsynonymous variant in FOS. Eighty-one percent
of the boxers (n = 16) are heterozygous or homozygous for the
Table 5. Top somatic copy number alterations
SCNA descriptora Q-values after peak arbitration Peak limits Comment B versus T, t-test (two-tail, type 2)
8q11.2 (deletion) 2.98 × 10−19 Chr8:2869427–2882658 TCR 1.72 × 10−7
8q33.3 (deletion) 8.14 × 10−15 Chr8:72990670–73028555 Part of IGH gene 4.51 × 10−2
26q23 (deletion) 3.52 × 10−13 Chr26:27585064–27602759 Part of IGL gene 5.51 × 10−2
27q22.1 (deletion) 1.01 × 10−7 Chr27:35640457–35649322 KLRK1
11q15 (deletion) 1.81 × 10−7 Chr11:41264940–41305867
16q12 (deletion) 3.15 × 10−7 Chr16:6774247–6793678
13q21.1 (amplification) 7.77 × 10−6 Chr13:37810498–37816495
26q23 (amplification) 2.48 × 10−5 Chr26:27303323–27354974
18q12 (deletion) 8.94 × 10−5 Chr18:11622188–11700181
6q21.3 (amplification) 2.56 × 10−4 Chr6:38834153–38845543 PKD1
8q33.3 (amplification) 2.70 × 10−4 Chr8:72851488–72862981
24q25 (amplification) 6.28 × 10−4 Chr24:47029779–47110403
24q25 (deletion) 8.95 × 10−4 Chr24:44492687–44530980
20q17 (amplification) 1.25 × 10−3 Chr20:57364803–57378205
18q22.1 (amplification) 1.69 × 10−3 Chr18:25723457–25727487
31q15.1 (amplification) 1.69 × 10−3 Chr31:29912719–30091933
10q14 (amplification) 1.74 × 10−3 Chr10:17021157–17029882
28q18 (amplification) 1.74 × 10−3 Chr28:40745394–40855815
32q11.2 (deletion) 1.95 × 10−3 Chr32:13499741–14258756
a(SCNA) Somatic copy number alterations.
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variant, compared to 4% of the non-boxers (n = 210). The variant,
on canine Chr 8: 48333412, changes a serine to an isoleucine and
is predicted to be “probably damaging” by PolyPhen-2 (Adzhubei
et al. 2010). It is, however, impossible to say if this variant is linked
to the detected mutation frequency in the PTEN-mTOR pathway
in boxers without further analysis.
Themost significantlymutated genes inGr T-cell lymphomas
are PSMA1, the cytochrome C oxidase subunit COX8A, and leuko-
triene A4 hydrolase (LTA4H). LTA4H and PSMA1 have not been as-
sociated with human T-cell lymphoma, but have been associated
with other human cancers (Chen et al. 2003; Onken et al. 2010;
Jansen et al. 2012) and indicate new treatment options for Gr T-
cell lymphoma. Proteasome subunit gene PSMA1 is significantly
mutated in both B- and T-cell lymphomas. COX8A is a cyto-
chrome c oxidase subunit, which is involved in apoptosis (Liu
et al. 1996). Inhibition of LTA4H is associatedwith chronic inflam-
mation (Snelgrove et al. 2010; Wells et al. 2014), andmutations in
this genemay reflect de-differentiation of the tumor, although the
recurrent nature of the mutations rather suggests a gain-of-func-
tion mutation.
T-cell lymphoma tumors from both boxers and golden re-
trievers also have significant mutations in separate members of
the NLRP gene family. Those two members have not previously
been implicated in cancer.NLRP5 is significantly mutated in gold-
en retriever lymphomas, and NLRP14 is significantly mutated in
boxer lymphomas (Table 2).
Discussion
Breeding to select for phenotypic traits in dogs has created genetic
isolates (breeds) that not only present with wide morphologic var-
iation, but also have developed differential predispositions to dis-
ease. Using different breeds, we see that the twobreeds predisposed
to B-cell lymphoma have large overlaps in commonly mutated
genes and pathways, whereas T-cell lymphomas from two predis-
posed breeds are very different. There is no population structure
between those three breeds. The breeds diverged from the ancestral
dog population independently and at essentially the same time
(Vaysse et al. 2011), so the similarity between B-cell lymphomas
cannot be explained by higher relatedness between the predis-
posed breeds. In particular, the B-cell lymphomas are strikingly
similar to human B-cell lymphomas. We see recurrent mutations
affecting NF-κB signaling and histone modifiers, both of which
are typically seen in human DLBCL. The two T-cell lymphoma
breeds typically develop different types of T-cell tumors, and their
mutation patterns are more different. This raises the possibility
that genetic background predisposes to different subtypes of T-
cell lymphoma and may help dissect the genetic underpinnings
of different T-cell types. It is therefore important to understand
which human lymphoma subtypes the lymphomas in different
breeds are most similar to.
The difference in mutation pattern between T-cell lympho-
mas from boxers and golden retrievers is particularly interesting.
Boxers often develop lymphoblastic T-cell lymphomas as well as
peripheral T-cell lymphoma (PTCL) (Lurie et al. 2008), both aggres-
sive forms of T-cell lymphoma (Frantz et al. 2013), whereas golden
retrievers are more prone to developing T-zone lymphomas that
are relatively mild and have not been described in humans
(Fosmire et al. 2007; Seelig et al. 2014). The typical mutation pat-
tern in those two breeds is remarkably distinct. Due to the number
of different subtypes present in each breed and the number of in-
dividuals without subtype information available in this study, it is
impossible to say whether the genetic differences between sub-
types are smaller or larger than the genetic difference between tu-
mors from different breeds (Supplemental Material). Further















































FBXW7 amino acid / codon number
Figure 3. The same amino acid in FBXW7 is recurrently mutated in human and dogs. (Upper) Canine FBXW7 mutations show recurrent targeting of
amino acid R470. (Lower) A subset of the mutations reported in various human cancers (TumorPortal) (Lawrence et al. 2014) shows recurrent mutations




subtype, which has a genetic predisposing component, or if
somatic mutations directly reflect genetic background, or a combi-
nation thereof. The mutations in PTEN-mTOR pathway in half
(44%) of all Bx T-cell lymphomas suggest that this pathway is high-
ly important for the formation of aggressive lymphomas. In hu-
man cancers, PTEN is most commonly lost in endometrial
cancer and glioblastoma (Lawrence et al. 2014). Uterine cancers
are generally uncommon among all US dogs due to spaying prac-
tices, but boxers have an increased frequency of glioma. It can be
speculated that boxers may be “predisposed” for a mutation in
this pathway—that is, that their genetic background gives them
an increased sensitivity for such mutations. Interestingly, 81% of
all the boxers sequenced here carry a germline variant in FOS.
Only 4% of the exome-sequenced non-boxer dogs (n = 210) carry
this variant. As the FOS transcription factor controls some of the
same downstream targets of the PTEN-mTOR pathway (Koul
et al. 2007; De Marco et al. 2013), it is possible that the genetic
background of a boxer could make themmore sensitive to a muta-
tion in the PTEN-mTOR pathway in relevant cell types compared
to the average dog. It has been shown that genetic background pre-
disposes to specific cancers, even specific lymphoma subtypes.
This could happen through the genetic background making the
individual more sensitive to mutations in specific cancer genes
that determine disease subtype. Genetic background also affects
overall tumor mutation load, as evident from the lower somatic
mutation frequency in golden retrievers compared with the two
other breeds.
The B-cell lymphomas may also be subdivided based on their
mutation profile. TRAF3-TRAF2-BIRC2-BIRC3-MAP3K14 are mu-
tated in 30% of all B-cell lymphomas, and 50% of all Cs B-cell lym-
phomas, which is about the same fraction as human DLBCL
tumors with dysregulated canonical or noncanonical NF-κB path-
ways (Compagno et al. 2009). In contrast to the T-cell lymphomas,
we see very few differences in significantlymutated genes between
B-cell lymphomas for the two studied breeds. This certainly reflects
a more uniform mutation pattern, but it is possible that there are
subtle differences between the two breeds that we do not pick up
because of the relatively low number of cocker spaniel samples in-
cluded in this study. For example, FBXW7 appears to be more re-
currently mutated in B-cell lymphomas from golden retriever
compared to cocker spaniels, but this difference is not statistically
significant.
The recurrent mutations in specific genes and pathways are
likely reflecting the relatively homogeneous genetic background
of each breed, allowing us to identify molecular subtypes based
on genetic background. Such genetic backgrounds may be exem-
plified by the two loci predisposing to B-cell lymphoma and
hemangiosarcoma in golden retrievers (found by genome-wide as-
sociation mapping), which are associated with differential expres-
sion of immune-related genes, including BIRC3 (Tonomura et al.
2015). These results point to a mechanism involving altered
T-cell activation as a strong predisposing factor in this breed. All
three breeds analyzed here for lymphoma tumor mutation also
have an increased incidence of autoimmune disorders like atopic
dermatitis. The risk of developing several lymphoma subtypes, in-
cluding DLBCL, is elevated in patients with autoimmune diseases
like Sjögren’s syndrome and SLE (lupus) (Smedby et al. 2006). This
could suggest that the lymphoma predisposition in the breeds
comes from an unbalanced immune regulation.
Several of the recurrently mutated genes have not previously
been implicated in human lymphoma, includingNLRP5, NLRP14,
and GRIFIN. This follows the pattern reported previously in hu-
man studies, suggesting that the majority of mutations specific to
certain cancer subtypes or relatively rare mutations have not yet
been reported (Lawrence et al. 2014). Those novel mutations, and
mutations reported in other cancers but not lymphoma, may indi-
cate novel treatment possibilities in lymphoma. Generally, the
same chemotherapeutic agents are effective in both dogs and hu-
mans (Honigberg et al. 2010; London et al. 2014). Hence, it is high-
ly likely that the significantly mutated genes identified in dogs are
suggestive of genes and pathways involved in human lymphoma,
possibly allowing new treatment options. Several of the most sig-
nificantly mutated genes in dogs, such as MITF, FKBP3, and
LTA4H, have been identified in a small proportion of human lym-
phoma cases, suggesting that the homogeneous genetic back-
ground of dog breeds may highlight mutations important for,
and possibly guiding treatment for, a subset of human patients.
Looking at themost significantly mutated genes in B-cell and
T-cell lymphomas across the three studied breeds, genes not previ-
ously implicated in human lymphoma include well-known can-
cer-associated genes such as LTA4H and PSMA1, indicating
potential treatment with proteasome inhibitors. In contrast,
TBC1D26 is a novel cancer gene, which may allow for completely
new treatments. TBC1D26has not beenwell characterized, but be-
longs to a family of proteins in which other members have been
implicated in cell cycle control. TBC1D26 paralogs are mutated
in 17% of all samples, with the ENSCAFG00000025100 paralog be-
ing the most commonly mutated, and the mutations cluster in a
few domains. Additionally, each T-cell lymphoma predisposed
breed is significantly mutated in a different member of the NLRP
gene family, which is primarily associated with a role in innate im-
munity (Pedraza-Alva et al. 2015) as well as reproduction (Duéñez-
Guzmán and Haig 2014).
Canine studies may bemore translational at the pathway lev-
el than at the gene level for example histone acetyltransferases and
methyltransferases are recurrently mutated in human lympho-
mas; and although the exact genes only partially overlap, other
histonemodifiers aremutated in the dog. This affirms the observa-
tion that the mechanisms of lymphoma overlap strongly between
humans and dogs.
In conclusion, our results highlight how the spontaneously
occurring lymphomas in purebred dogs can be very helpful in
characterizing different tumor molecular subtypes, which should




Tissue samples (lymph node with tumor and matched blood or
healthy lymph node) were provided by coauthors, veterinary hos-
pitals, or obtained from the Pfizer Canine Comparative Oncology
and Genomics Consortium (CCOGC) Biospecimen Repository.
Investigators at other institutions may have received specimens
from the same subjects from CCOGC. Naïve (newly diagnosed
and untreated) disease was one of the eligibility criteria for partic-
ipation. For lymph node details, see Supplemental Material.
Immunophenotyping
Immunophenotyping informationwas suppliedwith the samples,
or determined by immunohistochemistry using CD3/CD79A
markers, or by PARR (Burnett et al. 2003). Subtyping information
(DLBCL, TZL, PTCL, etc.) was only available for one-third of the
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samples and hence not considered for the analysis (see
Supplemental Material).
Library construction and sequencing
Dog exome libraries were generated from standard indexed
Illumina libraries using a custom Roche/Nimblegen solution-
based capture library (120705_CF3_Uppsala_Broad_EZ_HX1) fol-
lowing the protocol provided. The libraries capture 85% of the ca-
nine exonic regions. Per suggestion from Nimblegen, developer’s
reagent (06684335001) was used in place of COT-1. Index-specific
hybridization enhancing oligos were used.
Alignment and filtering
After capture, tumor andnormal indexed libraries were pooled sep-
arately into groups of eight. All pools were run on an Illumina
HiSeq 2000 platform,with coverage targets of 30× for normal pools
and 60× for tumor pools.
The reads were aligned to the CanFam3.1 reference genome
(Hoeppner et al. 2014) using BWA 0.5.9 (Li and Durbin 2009).
Using the Picard tool kit (http://broadinstitute.github.io/picard/),
the duplicate reads were marked, and the data were sorted. Using
the Genome Analysis Toolkit (GATK) software, local realignments
were generated with cocleaning of tumor/normal sample pairs,
and base quality scores were recalibrated per GATK Best Practices
(Van der Auwera et al. 2013). Samples with fewer than 50% of tar-
get bases covered to 10× were removed.
Variant calling
GATK 2.6 (DePristo et al. 2011) was used to realign the reads
around indels. MuTect 1.1.4 (http://www.broadinstitute.org/
cancer/cga/mutect) and IndeLocator (http://www.broadinstitute
.org/cancer/cga/indelocator) were used to call SNPs and indels, re-
spectively, on the resulting BAM files. Samples with more than 5
SD more variants than the mean were removed since this may re-
flect incorrect pairing of tumor and normal DNA. MuTect uses a
statistical model to determine the likelihoods based on the reads
of a position being at least partially nonreference in tumor and
of being homozygous reference in normal. If these likelihoods
are high enough, it concludes that a somatic event has hap-
pened. Variants considered by these programs to be somatic rather
than germlinewere retained, and SnpEff 3.3 (Cingolani et al. 2012)
was used to predict the possible effects of these variants. Although
SnpEff reports all possible effects of a particular variant, we re-
tained only one effect for each variant, choosing that which was
judged to bemost impactful. The resultingVCF fileswere compiled
into a single MAF file using custom code.
Variant filtering
The somatic variants were filtered to remove false positives due
to germline population variation. This was done in two steps:
First, previously known population variation was removed from
the somatic set (Lindblad-Toh et al. 2005; Vaysse et al. 2011;
Axelsson et al. 2013) and supplemented with additional variants
identified by Erik Axelsson (E Axelsson and K Lindblad-Toh,
unpubl.). Second, variants were removed that were found to be
present in a panel of normal canine samples. Variants in these nor-
mal sampleswere called using SAMtools 1.1 andBCFtools 1.1 (http
://www.htslib.org/). Normal variants were considered “true” if the
Phred-scaled likelihood score of being homozygous reference at
that position was greater than 50, meaning, if it was sufficiently
likely that at least one allele was variant. The variant was “trusted”
if the same variant was true in two or more samples. Indels could
additionally be considered trusted if two ormore indelswere found
to be true at that position (including the indel in question). All
trusted variants were filtered out of the MuTect output files.
Subsequently, putatively somatic variants within immunoglobu-
lin genes and T-cell receptors (where variation is likely not reflect-
ing the tumor) and those in olfactory receptors were removed.
Finally, the top 25 significantly mutated genes from each breed
group were scored for recurrent mutations. These were evaluated
manually in IGV (Thorvaldsdóttir et al. 2012) and removed if the
variantwas considered highly likely to be a false positive, for exam-
ple, because of read alignment problems due to insufficient
cocleaning or if the vast majority of variants were supported by
reads whose mate aligned to another chromosome with strong
similarity to this region.
Significantly mutated genes
The filtered mutation file, along with the original BAM files and
Ensembl’s dog annotation v.75 (Hoeppner et al. 2014) were run
through Genome MuSiC 0.4 (Dees et al. 2012) to produce a list
of significantly mutated genes. Default settings were used, except
if multiple mutations were seen in a gene in one individual, they
were counted as one (“merge concurrent” option). Multiple muta-
tions in a gene could reflect mutations in different subclones, mu-
tations in both gene copies in one cell, or several mutations
targeting function, but it could also arise from lower purifying
selective pressure on a gene whose function was already lost.
Pathway analysis
Ingenuity pathway analysis (http://www.ingenuity.com) was used
for pathway analysis using standard settings. Human gene names
and MuSiC CT P-values were used. For analysis using DAVID
(Huang da et al. 2009a,b), the top 15 (or all, if less than 15) signifi-
cantly mutated genes were inputed as “gene list.”
SCNA
Somatic copy number alterations were estimated from exome data
by adapting the SegSeq algorithm (Chiang et al. 2009). Only 40
dogs could be used due to a recurrent artifact pattern, hence, all
samples were analyzed together. DNA segments subject to somatic
copy number alterations were analyzed with GISTIC 2.0 (Mermel
et al. 2011).
Data access
The sequence data from this study have been submitted to the
NCBI Sequence Read Archive (SRA; http://www.ncbi.nlm.nih.gov/
sra/). Accession numbers are listed in Supplemental Table S10.
Somatic and germline variants have been deposited in NCBI
dbSNP (http://www.ncbi.nlm.nih.gov/SNP/) under the assay IDs
(ss#) listed in the SupplementalMaterial, and have been integrated
into the “Broad Improved Canine Annotation v1” track hub at the
UCSC Genome Browser (http://genome.ucsc.edu/cgi-bin/hgHub
Connect). The tracks are called “Lymphoma som SNPs” and
“Germline PON SNPs,” respectively.
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